Pharmaceutical Technology

FEBRUARY 6, 2023

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263

Protein Research Antibody Immune Response 263

Pharmaceutical Technology

JULY 20, 2022

Researchers at Gladstone Institutes and UC San Francisco (UCSF) have discovered in a study that bromodomain and extraterminal (BET) proteins are vital for the body to fight Covid-19 infection. . The research also found that BET proteins play two distinct roles in affecting how the SARS-CoV-2 virus interacts with human cells. .

Protein 278

Protein Scientist Gene DNA 278

pharmaphorum

APRIL 11, 2024

Novartis accelerates its protein degrader programmes by licensing a phase 3-ready prostate cancer candidate from Arvinas in a deal worth over $1 billion

Protein 94

Protein Licensing Licensing 94

Pharmaceutical Technology

MARCH 26, 2024

Discover Innovent Biologics' groundbreaking patent for novel proteins with heterodimeric antibody Fc, revolutionizing antibody engineering and drug development.

Protein 130

Protein Engineer Antibody Development 130

Pharmaceutical Technology

MARCH 28, 2024

Pharmaceutical Technology has listed the leading protein and peptide synthesis solutions and suppliers. Download for free here.

Protein 130

Protein Manufacturing 130

Bio Pharma Dive

MARCH 22, 2023

Armed with a $50 million Series A round, the startup is building off of research from a lab run by protein engineering pioneer Jim Wells.

Protein 357

Protein Engineer Research 357

Bio Pharma Dive

MARCH 27, 2023

A closely watched meeting showed the FDA’s own external advisers think that effects on this protein, known as neurofilament, could be enough to warrant conditional approval of certain drugs.

Protein 324

Protein Drugs 324

BioSpace

APRIL 16, 2024

As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.

Protein 110

Protein Licensing Licensing 110

Pharmaceutical Technology

MARCH 26, 2024

Discover how Arcturus Therapeutics' patent for a modified human OTC protein revolutionizes OTC deficiency treatment with codon optimized mRNA sequences.

Protein 130

Protein 130

BioSpace

NOVEMBER 28, 2023

In a deal with Tokyo-based PRISM BioLab, Eli Lilly will gain access to the Japanese biotech’s proprietary platform to develop small molecule inhibitors of protein-protein interactions.

Protein 112

Protein Development 112

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Bromodomain Containing Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Containment 130

Containment Protein Development Drugs 130

Bio Pharma Dive

AUGUST 25, 2021

The pharma has struck its second research pact focused on drugs that break down harmful proteins in as many years, this time with California biotech Lycia Therapeutics.

Protein 280

Protein Drugs Research 280

Bio Pharma Dive

AUGUST 2, 2022

It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.

Protein 268

Protein Development Drugs 268

Bio Pharma Dive

JUNE 14, 2023

The alliance is Astellas’ second recent partnership involving protein degraders, an emerging area of drug research the company has made a focus in recent years.

Protein 169

Protein Drugs Research 169

Pharmaceutical Technology

MARCH 11, 2024

is revolutionizing cancer treatment with their patented macrocyclic compounds targeting Ras proteins. Discover how Revolution Medicines Inc. Learn more about their potential impact on various types of cancer and Ras mutations.

Protein 100

Protein Medicine 100

Pharmaceutical Technology

SEPTEMBER 18, 2023

The ability to detect host-cell proteins in bioprocessing streams is a vital tool in pharmaceutical firms' product purification arsenal

Protein 130

Protein Production 130

BioSpace

APRIL 11, 2024

Novartis on Thursday announced that it is making $150 million in upfront payments to protein degradation biotech Arvinas, while separately revealing that its tender offer for MorphoSys has begun.

Protein 92

Protein 92

Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.

Protein 130

Protein Development Licensing Licensing 130

Drug Discovery World

APRIL 17, 2024

Arvinas’ AR-V7-targeting PROTAC protein degrader is designed to target both AR-V7 and full-length AR. This strategic transaction also further validates our innovative PROTAC protein degrader platform and its potential to deliver new treatments.”

Protein 52

Protein Licensing Licensing Sales 52

Pharmaceutical Technology

JULY 25, 2023

Astellas Pharma has entered a research partnership and licence agreement with PeptiDream for the discovery of new targeted protein degraders.

Protein 130

Protein Research 130

Pharmaceutical Technology

DECEMBER 7, 2023

GlobalData’s report assesses the drugs in the Cholesteryl Ester Transfer Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase JAK1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Myc Proto Oncogene Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 130

Protein Development Drugs 130

Bio Pharma Dive

DECEMBER 6, 2022

Entact Bio aims to develop medicines that can enhance helpful proteins, rather than block harmful ones, a twist on the usual drugmaking playbook.

Protein 204

Protein Medicine Development 204

Bio Pharma Dive

JULY 28, 2022

Vicinitas and its protein-stabilizing research have attracted $65 million from a group of investors that includes a16z, Deerfield and GV.

Protein 258

Protein Research 258

Bio Pharma Dive

JANUARY 27, 2022

Backed by some of biotech's most powerful investors, Septerna is looking to usher in the next chapter of medicines that act on G protein-coupled receptors.

Protein 312

Protein Medicine Drugs 312

Pharmaceutical Technology

DECEMBER 7, 2023

GlobalData’s report assesses the drugs in the Protein Kinase C Theta Type pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins. These regions are critical for optimal interactions between proteins.

Protein 126

Protein Gene Bioassay DNA 126

Pharma Times

DECEMBER 20, 2023

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. Estimated to affect over 8.5 However, its relation to dopaminergic neuron death is unclear.

Protein 94

Protein Medicine Engineer Genetics 94

Pharmaceutical Technology

MARCH 11, 2024

is revolutionizing adoptive cell transfer therapies with patented methods to reduce HLA-A protein expression in engineered human cells. Discover how Intellia Therapeutics Inc. Explore the potential for treating cancer, infectious diseases, and autoimmune disorders.

Protein 130

Protein Genetics Engineer 130

Pharmaceutical Technology

AUGUST 9, 2023

The proteins, which mimic those found in mother’s milk, target toxins released by harmful pathogens in the gut.

Protein 130

Protein Development 130

XTalks

NOVEMBER 29, 2023

In a significant move towards revolutionizing the alternative dairy protein market, cell programming and biosecurity platform Ginkgo Bioworks has joined forces with Vivici BV , an innovative business-to-business (B2B) ingredients startup. This process ensures optimal protein expression and functionality at a commercial scale.

Protein 105

Protein Production Marketing Development 105

XTalks

SEPTEMBER 27, 2023

EQUII, a food tech startup renowned for its protein bread that focuses on high complete protein and low carbs, is expanding its product line. This new range, which debuted at Expo East last week, includes Plain and Multigrain protein bread, delivering consumers a blend of nutrition without compromising on flavor.

Protein 59

Protein Branding Containment Production 59

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. GS-6791 is the first development candidate from the previous collaboration between Gilead Sciences and Nurix in 2019.

Protein 130

Protein Licensing Licensing Sales 130

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. Sillajen and Advaxis are the other key patent filers of oncolytic viral proteins.

Protein 130

Protein Gene Genetics Gene Therapy 130

Pharmaceutical Technology

DECEMBER 22, 2023

Enhance protein expression and cellular targeting for effective treatment of genetic disorders. Discover Amicus Therapeutics' groundbreaking gene therapy vectors and methods of use. Explore the patent claim now!

Gene Therapy 100

Gene Therapy Protein Gene Genetics 100

Pharmaceutical Technology

FEBRUARY 16, 2023

Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors.

Protein 147

Protein Development Sales Business Development 147